Infection in Tumor Surgery

Key Points

· Infection after tumor surgery is more frequent than after routine orthopedic procedures because these operations involve extensive dissection, prolonged operative time, large dead space, major implants, and a patient population that is often medically fragile.

· Risk is especially high after pelvic resections, megaprosthetic reconstruction, repeat surgery, radiotherapy, and systemic chemotherapy.

· Diagnosis can be difficult because wound complications, post-operative inflammation, implant-related pain, and even local tumor recurrence may resemble infection.

· Treatment is often demanding and may require repeated debridement, staged reconstruction, soft tissue coverage procedures, prolonged antibiotics, or even amputation in extreme cases.

· Infection in oncologic reconstruction is not only a surgical complication; it can delay adjuvant therapy, compromise limb salvage, and affect overall oncologic outcome.

Introduction

Infection remains one of the most serious complications in musculoskeletal tumor surgery. Compared with standard trauma or arthroplasty practice, the infection burden in orthopedic oncology is distinctly higher. The reasons are multifactorial: patients may be immunosuppressed, resections are often wide, soft tissue coverage may be limited, operative duration is usually long, and reconstruction frequently relies on megaprostheses or other complex implants. Once infection develops, management becomes considerably more difficult than in conventional orthopedic settings because infection control must be balanced against oncologic safety, limb function, implant durability, and the need to maintain systemic cancer treatment.

Why Infection Is Different in Tumor Surgery

· Tumor resections often create large cavities and devascularized tissue planes that favor bacterial persistence.

· Endoprosthetic reconstruction introduces a large foreign-body surface, which increases the risk of biofilm formation and makes eradication more difficult.

· Soft tissue quality is frequently poor because of prior surgery, radiotherapy, scar formation, or tumor-related destruction.

· Chemotherapy, malnutrition, anemia, and general physiologic stress reduce host defense and impair wound healing.

· Any infectious complication may interrupt or postpone chemotherapy, radiotherapy, rehabilitation, and weight-bearing progression.

Risk Factors

· Immunosuppression related to chemotherapy or advanced malignancy

· Malnutrition, cachexia, anemia, and hypoalbuminemia

· Diabetes mellitus, smoking, obesity, renal dysfunction, and other systemic comorbidities

· Poor general performance status and limited physiologic reserve

· Large tumor size requiring extensive resection

· Pelvic, sacral, proximal femoral, and other anatomically demanding locations

· Tumors associated with major soft tissue loss or ulceration

· Previous radiotherapy with impaired vascularity and reduced healing potential

· Recurrent tumors requiring surgery through scarred or previously contaminated tissue planes

· Long operative time and substantial blood loss

· Use of megaprostheses or other large implant constructs

· Creation of extensive dead space after tumor resection

· Need for revision surgery, repeat exposure, or re-reconstruction

· Inadequate soft tissue coverage or wound closure under tension

Classification

1. Time-based classification

· Early infection: usually within the first 4 weeks after surgery

· Delayed infection: between 1 and 12 months

· Late infection: beyond 12 months, often related to hematogenous spread or chronic low-grade contamination

2. Anatomic classification

· Superficial infection involving skin and subcutaneous tissue

· Deep infection involving fascia, bone, implant, or the reconstructed segment

3. Clinical behavior

· Acute postoperative infection with drainage, erythema, pain, and systemic signs

· Chronic low-grade infection with persistent pain, delayed wound healing, sinus formation, or implant loosening

· Hematogenous infection presenting after a previously stable reconstruction

Clinical Presentation

· Persistent wound drainage or delayed wound healing

· Increasing erythema, swelling, local warmth, and tenderness

· Pain that worsens after an initial period of expected post-operative improvement

· Fever or malaise, although these may be absent in immunocompromised patients

· Fluid collection, abscess formation, or sinus tract development in more established cases

A crucial practical point is that infection and local tumor recurrence may produce similar symptoms and imaging findings. New pain, swelling, or a mass around a reconstruction should never be dismissed without careful evaluation.

Diagnosis

1. Laboratory evaluation

· C-reactive protein and erythrocyte sedimentation rate are useful adjuncts but are not specific.

· Leukocytosis may be absent, particularly in patients receiving chemotherapy or those with chronic low-grade infection.

· Serial values are often more informative than a single isolated measurement.

2. Imaging

· Plain radiographs may show soft tissue swelling, peri-implant lucency, implant migration, or late loosening.

· Ultrasound can help identify superficial collections and guide aspiration in selected cases.

· CT or MRI may define abscesses, fluid collections, and local soft tissue status, although metal artifact often limits interpretation.

· Nuclear imaging and PET-based studies may be considered in difficult cases, but these findings must be interpreted cautiously in the post-operative oncologic setting.

3. Microbiology and tissue diagnosis

· Deep aspirates or intraoperative tissue cultures are far more valuable than superficial swabs.

· Multiple deep samples improve diagnostic accuracy.

· Culture-negative infection does not exclude the diagnosis, especially after previous antibiotic exposure.

· Histologic evaluation may be useful when the distinction between infection, inflammation, and recurrence is unclear.

Treatment Algorithm

1. Suspected early infection

· Early recognition is essential because there is a limited window in which implant retention may still be realistic.

· If the reconstruction is mechanically stable and the infection is recognized early, irrigation and aggressive debridement with implant retention may be attempted.

· This strategy should be combined with targeted antimicrobial therapy once cultures are available.

· The success of implant retention depends on prompt intervention, adequate debridement, a stable construct, and an organism that can be controlled medically.

2. Delayed or chronic infection

· Chronic infection around an oncologic reconstruction is much less likely to be eradicated without removing the implant.

· Two-stage revision remains the most widely accepted strategy in many deep implant-related infections.

· The first stage typically includes implant removal, extensive debridement, management of dead space, and temporary reconstruction or spacer placement when appropriate.

· After infection control, the second stage involves definitive reconstruction with careful attention to host status and soft tissue quality.

3. Megaprosthesis infection

· Megaprosthetic infection is particularly difficult because the implant surface is extensive and the host bed is often compromised.

· Repeated debridement may be necessary, but salvage becomes progressively less likely as biofilm matures and soft tissue quality deteriorates.

· In selected patients, chronic suppressive antibiotics may be used when curative treatment is unrealistic or when surgical options are limited.

· Persistent uncontrolled infection may ultimately require resection arthroplasty, permanent spacer strategies, or amputation.

4. Soft tissue management

· Adequate soft tissue coverage is fundamental to successful infection control.

· When closure is tenuous, early involvement of plastic surgery for rotational or free flap coverage may be decisive.

· Failure to correct the soft tissue problem often leads to failure of the entire reconstruction, regardless of antibiotic choice.

5. Antibiotic strategy

· Antibiotics should follow appropriate sampling whenever the patient is clinically stable enough to permit culture acquisition.

· Empiric therapy may be necessary in septic or rapidly deteriorating patients, but definitive regimens should be culture-directed whenever possible.

· Duration depends on the extent of infection, implant status, organism, host condition, and the chosen surgical strategy.

Special Considerations in Orthopedic Oncology

· Infection may delay adjuvant chemotherapy, which can be particularly consequential in high-grade sarcoma.

· Radiated tissue heals poorly and is less tolerant of repeat surgery.

· A reconstructed limb may be technically salvageable but functionally poor after repeated infection-related procedures.

· Amputation in this setting is not simply a failure of reconstruction; in some cases it becomes the safest and most definitive oncologic and septic solution.

Prognostic Impact of Infection

· Higher reoperation rates and prolonged hospitalization

· Delayed rehabilitation and reduced final function

· Increased risk of reconstruction failure and secondary amputation

· Interruption of systemic oncologic treatment

· Substantial psychological burden and reduced quality of life

Even when infection is eventually controlled, the cumulative effect of repeated surgery, immobilization, delayed therapy, and soft tissue loss can profoundly alter the patient’s overall course.

Prevention Strategies

· Optimize nutrition, glycemic control, anemia, and general medical condition before surgery whenever possible.

· Plan the resection and reconstruction carefully to reduce unnecessary operative time and contamination.

· Use appropriate perioperative antibiotic prophylaxis and extend protocols selectively in high-risk settings when clinically justified.

· Reduce dead space, protect soft tissues, and avoid wound closure under excessive tension.

· Consider antibiotic-loaded cement or other adjunctive local strategies when suitable for the reconstruction method.

· Maintain close early follow-up so that wound problems are recognized before they evolve into established deep infection.

Practical Pearls

· Infection in tumor surgery is often a treatment-defining event rather than a routine post-operative complication.

· Always keep both infection and recurrence in mind when evaluating new pain or swelling around an oncologic reconstruction.

· In early deep infection, time matters; delayed debridement reduces the chance of implant salvage.

· When the soft tissue envelope is poor, reconstruction survival depends as much on coverage as on debridement and antibiotics.

· A mechanically impressive reconstruction has little value if infection control is not achievable.

Conclusion

Infection in tumor surgery remains one of the most demanding problems in orthopedic oncology. It is more common, more destructive, and more difficult to treat than infection in many other orthopedic settings. Successful management depends on early recognition, accurate distinction from recurrence, decisive surgical treatment, appropriate antimicrobial therapy, and attention to soft tissue biology. In many cases, optimal care requires close collaboration between orthopedic oncology, infectious disease, plastic surgery, radiology, pathology, and medical oncology teams.

References

1. Jeys LM, Grimer RJ, Carter SR, Tillman RM. Periprosthetic infection in patients treated for an orthopaedic oncological condition. J Bone Joint Surg Am. 2005;87(4):842-849.

2. Racano A, Pazionis T, Farrokhyar F, Deheshi B, Ghert M. High infection rate outcomes in long-bone tumor surgery with endoprosthetic reconstruction in adults: a systematic review. Clin Orthop Relat Res. 2013;471(6):2017-2027.

3. Henderson ER, Groundland JS, Pala E, et al. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011;93(5):418-429.

4. Lugowska I, Teterycz P, Mikula M, et al. Infection after bone tumor surgery: incidence, risk factors, and management. Orthop Traumatol Surg Res. 2020;106(6):1099-1106.

5. Hardes J, Gebert C, Schwappach A, et al. Characteristics and outcome of infections associated with tumor endoprostheses. Arch Orthop Trauma Surg. 2006;126(5):289-296.

6. Sendi P, Lötscher PO, Kessler B, Graber P, Zimmerli W. Management of periprosthetic joint infection following tumor prosthesis implantation. Clin Microbiol Infect. 2011;17(7):1047-1053.

7. Benevenia J, Kirchner R, Patterson F, et al. Periprosthetic infection after limb salvage surgery for bone tumors: a review of the literature and current concepts. J Surg Oncol. 2014;110(5):603-609.

8. Gosheger G, Gebert C, Ahrens H, et al. Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res. 2006;450:164-171.

9. Şirin, E., Sofulu, Ö., Baysal, Ö., Akgülle, A. H., & Erol, B. (2023). Staged management of infection with adjustable spacers after megaprosthesis implantation in primary sarcoma patients. Indian Journal of Orthopaedics, 57(6), 938-947.

10. Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on Periprosthetic Joint Infection. Bone Joint J. 2013;95-B(11):1450-1452.